PMID- 1505560
OWN - NLM
STAT- MEDLINE
DCOM- 19920923
LR  - 20190509
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 13
IP  - 8
DP  - 1992 Aug
TI  - A double-blind, parallel-group comparison of flosequinan and enalapril in the 
      treatment of chronic heart failure.
PG  - 1092-100
AB  - The effects of flosequinan and enalapril on exercise capacity (bicycle exercise 
      duration), quality-of-life symptomatology (visual analogue scales) and New York 
      Heart Association (NYHA) grading, were compared in 61 patients with chronic heart 
      failure (NYHA, grade III). Bicycle exercise duration improved similarly with 
      flosequinan (+27%) and enalapril (+18%); in patients completing the study, 
      flosequinan produced a significantly greater increase in exercise time at week 
      12, compared with enalapril (P = 0.02). Improvements in visual analogue scores 
      relating to general health, energy and vitality, ability to perform physical 
      activities and breathing performance, were equivalent for both drugs. Changes in 
      NYHA classification showed that 27 (55%) of 49 patients completing the study had 
      improved by at least one NYHA grade (15 (68%) patients on flosequinan; 12 (44%) 
      on enalapril). The overall safety and tolerability of the two treatments was 
      similar; 18 patients reported adverse effects while on flosequinan, compared with 
      19 patients on enalapril. Neither treatment was associated with any clinically 
      important changes in haematological or biochemical variables, although some 
      treatment-related effects were observed. This study confirms that flosequinan 
      achieved similar efficacy to enalapril in the symptomatic relief of chronic heart 
      failure. The effect of flosequinan on survival in chronic heart failure has not 
      been tested; pending such studies, our data suggest that it may prove a useful 
      alternative therapy in patients where ACE inhibitors are contraindicated or 
      poorly tolerated.
FAU - Silke, B
AU  - Silke B
AD  - Department of Therapeutics and Pharmacology, Queen's University of Belfast, 
      Northern Ireland.
FAU - Tennet, H
AU  - Tennet H
FAU - Fischer-Hansen, J
AU  - Fischer-Hansen J
FAU - Keller, N
AU  - Keller N
FAU - Heikkila, J
AU  - Heikkila J
FAU - Salminen, K
AU  - Salminen K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Quinolines)
RN  - 0 (Vasodilator Agents)
RN  - 69PN84IO1A (Enalapril)
RN  - 6NB119DLU7 (flosequinan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chronic Disease
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Enalapril/*administration & dosage/adverse effects
MH  - Exercise Test/drug effects
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Hemodynamics/*drug effects/physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Quinolines/*administration & dosage/adverse effects
MH  - Vasodilator Agents/*administration & dosage/adverse effects
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.eurheartj.a060320 [doi]
PST - ppublish
SO  - Eur Heart J. 1992 Aug;13(8):1092-100. doi: 
      10.1093/oxfordjournals.eurheartj.a060320.